^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Ultra-Sensitive Signatera™ Genome MRD Test

    Company:
    Natera
    Type:
    Laboratory Developed Test
    Related tests:

    Details

    Evidence
    News
    Signatera Genome was able to detect circulating tumor DNA (ctDNA) significantly ahead of clinical recurrence with excellent performance. In addition, postsurgical Signatera-positive patients had inferior recurrence-free survival compared to Signatera-negative patients, consistently across the different cancers that were evaluated. Additional clinical utility data on the Signatera Genome assay, including predictive data, will be presented at the conference.
    Cancer:
    Breast Cancer, Colorectal Cancer, Melanoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma
    Method:
    RNA/DNA-based molecular screening test